Close



Nov 13, 2023 05:33AM
Nov 12, 2023 09:00AM
Oct 26, 2023 08:00AM
Aug 9, 2023 06:30AM
Jul 31, 2023 08:00AM
Jul 26, 2023 08:01AM
Jul 26, 2023 08:00AM Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
Jun 21, 2023 09:01AM
Jun 1, 2023 06:00AM
Jun 1, 2023 06:00AM
May 12, 2023 11:00AM
May 3, 2023 07:00AM
Mar 16, 2023 08:02AM
Mar 16, 2023 08:00AM Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
Mar 16, 2023 08:00AM
Mar 6, 2023 08:09AM
Mar 6, 2023 08:00AM
Mar 6, 2023 08:00AM
Mar 5, 2023 10:21AM
Mar 5, 2023 10:21AM
Mar 1, 2023 07:00AM Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 1, 2023 07:00AM
Feb 27, 2023 08:01AM
Feb 27, 2023 08:00AM
Feb 27, 2023 08:00AM
Jan 10, 2023 07:17AM
Jan 10, 2023 07:15AM
Jan 10, 2023 07:15AM Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
Nov 7, 2022 08:00AM
Nov 7, 2022 08:00AM
Oct 27, 2022 07:00AM
Oct 27, 2022 07:00AM
Aug 28, 2022 05:51AM
Aug 28, 2022 05:51AM
Aug 26, 2022 08:19AM New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
Aug 26, 2022 08:19AM
Aug 15, 2022 08:01AM
Aug 15, 2022 08:00AM
Aug 15, 2022 08:00AM
Aug 3, 2022 07:00AM
Aug 3, 2022 07:00AM
Jun 30, 2022 04:06PM Amarin Corp. (AMRN) Announces REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
Jun 30, 2022 04:05PM
Jun 30, 2022 04:05PM
Jun 10, 2022 06:00AM
Jun 10, 2022 06:00AM
Jun 10, 2022 06:00AM
Jun 6, 2022 08:33AM
Jun 6, 2022 08:30AM Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
Jun 6, 2022 08:30AM

240,055 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All